This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Adcendo, MSD Collaborate on...
Business clinical trial collaboration

Adcendo, MSD Collaborate on ADCE-T02, KEYTRUDA

Analysis based on 6 articles · First reported May 26, 2026 · Last updated May 26, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This collaboration could positively impact the biotechnology and pharmaceutical markets by advancing new cancer therapies. For Adcendo, it signifies a major step in clinical development, potentially increasing its valuation. For Merck & Co., it expands the market potential and therapeutic applications of Pembrolizumab.

Biotechnology Pharmaceuticals
Event Summary

Adcendo ApS announced a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA). Under this agreement, ADCE-T02, Adcendo's tissue factor-targeting antibody-drug conjugate, will be evaluated in combination with Pembrolizumab (pembrolizumab), MSD's anti-PD-1 therapy, in a new Phase Ib study for patients with advanced solid tumors. Adcendo will sponsor the trial, and MSD will provide pembrolizumab. Both companies retain commercial rights to their respective compounds. The first patient dosing is anticipated in the second half of 2026. This collaboration aims to enhance anti-tumor activity through complementary mechanisms, potentially improving clinical outcomes for patients with cancers where tissue factor is overexpressed.

Entities Involved
priv
Adcendo
Adcendo has entered into a clinical trial collaboration and supply agreement with MSD to evaluate ADCE-T02 in combination with Pembrolizumab. This collaboration is a significant step for Adcendo in advancing its cancer therapies.
Importance 100.0 Sentiment 70.0
stock
Merck & Co.
Merck & Co., through its subsidiary MSD, will provide pembrolizumab (Pembrolizumab) for the Phase Ib clinical trial. This collaboration expands the potential applications of Pembrolizumab and strengthens its market position.
Importance 90.0 Sentiment 50.0
per
Lone Ottesen
Dr. Lone Ottesen, Chief Medical Officer of Adcendo, expressed excitement about the collaboration, highlighting the potential positive impact on clinical outcomes for cancer patients.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.